SIVEXTRO 200 MG TABLET
FDA nonproprietary name: tedizolid phosphate
For 30 tablets
Pharmacies pay
$14,273.71 filed
30 × $475.79029 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$12,637.91 filed
30 × $421.26363 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.89× estimated
Medicare paid 11% less than pharmacies pay.
Part D averages every strength and form sold under “Sivextro*” / “Tedizolid Phosphate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$16,419.77 estimated
$14,273.71 + $2,141.06 (15%) + $5.00 fee per fill = $16,419.77
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
SIVEXTRO 200 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as tedizolid phosphate, under the trade name “SIVEXTRO”.
FDA gives its dosage form as tablet, film coated and its route as oral.
The labeler, the company named on the label, is Merck Sharp & Dohme LLC.
FDA’s Established Pharmacologic Class for it is Oxazolidinone Antibacterial.
The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes); the FDA directory lists 2 of them.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $14,273.71 for 30 tablets (30 × $475.79029 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
All 3 NDCs
- 67919-0041-04 · Merck Sharp & Dohme LLC · $475.79029 per EA · eff. 2026-09-23 filed
- 67919-0041-05 · Merck Sharp & Dohme LLC · $475.79029 per EA · eff. 2026-09-23 filed
- 67919-0041-99 · not listed as a package in the FDA directory · $475.79029 per EA · eff. 2026-09-23 filed
What Medicare paid
Medicare Part D paid $12,637.91 for 30 tablets, at an average of $421.26363 per EA in 2024 (2024-01-01 to 2024-12-31) for “Sivextro*” and “Tedizolid Phosphate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 1,534 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for SIVEXTRO 200 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Sivextro* / Tedizolid Phosphate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. All 3 NADAC NDCs the name join matched to it have an FDA route including ORAL. 1 of the 3 NDCs that point at this name is not listed in the FDA NDC Directory as a package of its own; its route was taken from FDA's record for the same product (labeler and product code).